News Column

Findings from Radboud University Nijmegen Medical Center in Immunotherapy Reported

May 26, 2014



By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Investigators discuss new findings in Biotechnology. According to news originating from Nijmegen, Netherlands, by NewsRx correspondents, research stated, "Cancer immunotherapy critically relies on the efficient presentation of tumor antigens to T-cells to elicit a potent anti-tumor immune response aimed at life-long protection against cancer recurrence. Recent advances in the nanovaccine field have now resulted in formulations that trigger strong anti-tumor responses."

Our news journalists obtained a quote from the research from Radboud University Nijmegen Medical Center, "Nanovaccines are assemblies that are able to present tumor antigens and appropriate immune-stimulatory signals either directly to T-cells or indirectly via antigen-presenting dendritic cells. This review focuses on important aspects of nanovaccine design for dendritic cells, including the synergistic and cytosolic delivery of immunogenic compounds, as well as their passive and active targeting to dendritic cells."

According to the news editors, the research concluded: "In addition, nanoparticles for direct T-cell activation are discussed, addressing features necessary to effectively mimic dendritic cell/T-cell interactions."

For more information on this research see: Dendritic cell-based nanovaccines for cancer immunotherapy. Current Opinion In Immunology, 2013;25(3):389-95. (Elsevier - www.elsevier.com; Current Opinion In Immunology - www.elsevier.com/wps/product/cws_home/601305)

The news correspondents report that additional information may be obtained from L.E. Paulis, Dept. of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands. Additional authors for this research include S. Mandal, M. Kreutz and C.G Figdor (see also Biotechnology).

Keywords for this news article include: Antigen Presenting Cells, Biotechnology, Europe, Cancer, Nijmegen, Oncology, Immunology, Netherlands, Immunotherapy, Dendritic Cells, Immunomodulation, Mononuclear Phagocyte System.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters